Pander Jan, Gelderblom Hans, Guchelaar Henk-Jan
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, NL 2300 RC Leiden, The Netherlands.
Drug Discov Today. 2007 Dec;12(23-24):1054-60. doi: 10.1016/j.drudis.2007.10.016. Epub 2007 Nov 26.
Even though treatment of several types of solid tumours has improved in the past few years with the introduction of the monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), response rates to these targeted therapies are modest. Pharmacogenetic factors have the potential to select patients with higher chance of response to agents that target these pathways. This review provides an overview over germ-line variations in genes that are potentially involved in the pharmacodynamics of the monoclonal antibodies cetuximab, panitumumab and bevacizumab, and which may underlie variable anti-tumour response.
尽管在过去几年中，随着针对表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）的单克隆抗体的引入，几种实体瘤的治疗有所改善，但这些靶向治疗的缓解率并不高。药物遗传学因素有可能筛选出对靶向这些通路的药物反应机会更高的患者。本综述概述了可能参与西妥昔单抗、帕尼单抗和贝伐单抗单克隆抗体药效学的基因种系变异，这些变异可能是抗肿瘤反应差异的基础。
